Market Minds Advisory
Cell and Gene Therapy Clinical Trial Market

Cell and Gene Therapy Clinical Trial Market: Vein-to-Vein Logistics Redraw Trial Operations

Expanding cell and gene therapy pipeline breadth is pushing sponsors toward specialist trial operators who can manage vein-to-vein logistics ahead of generalist contract research organisations, sustaining demand for cold chain coordination.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$2.8BMarket Size 2025
2036 FORECAST VALUE$12.4BBase Case , 2026 to 2036
CAGR 2026 TO 203614.5 %Bull 15.8% / Bear 13.2%
INCREMENTAL OPPORTUNITY$9.2BNet 10- year value creation
EXPANSION MULTIPLE3.87x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Sponsors are shifting decisively toward specialist trial operators as vein-to-vein logistics complexity pushes generalist contract research organisations further down the vendor selection priority list this year, reshaping how biotech sponsors allocate clinical operations budgets across their expanding cell and gene therapy pipelines, and that shift is happening faster than expected.
Manufacturing and logistics support services are pulling ahead of every other category as sponsors chase deeper vein-to-vein coordination than generalist trial operators reliably deliver. North America concentrates the largest share of commercial volume given its exceptionally large cell and gene therapy biotech funding base and dense concentration of specialist trial operators headquartered domestically, while China is growing fastest as expanding domestic biotech pipeline investment and government cell therapy development funding pull volume toward domestic programmes.
Competitive character splits between large diversified contract research organisations defending broad sponsor supply relationships and specialist operators competing on niche logistics and manufacturing coordination categories. Tightening regulatory data management standards, combined with rising demand for autologous therapy trial support, are raising the operational bar that smaller regional operators increasingly struggle to clear without meaningful capital investment and dedicated regulatory affairs staff of their own.
Market Definition
The cell and gene therapy clinical trial market covers site management, manufacturing and logistics support, regulatory and clinical data management, patient recruitment and retention, and companion diagnostics services provided to sponsors running cell and gene therapy clinical trials. It excludes the therapies themselves, general contract manufacturing unrelated to clinical trial supply, and post-approval commercial distribution services.
Base Year Value
$2.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
14.5% base case. Bull 15.8%. Bear 13.2%.
Fastest Growth Segment
Manufacturing and Logistics Support Services: 18.2% CAGR
Fastest Growth Country
China: 16.8% CAGR
Fastest Growth Region
South Asia and Pacific: 16.6% CAGR
Largest Region
North America: 36% of 2025 global value
Market Leaders
IQVIA Holdings Inc., Thermo Fisher Scientific Inc., Parexel International Corporation, ICON plc, Charles River Laboratories International, Inc. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cell and Gene Therapy Clinical Trial Market Forecast Scenarios

cell-and-gene-therapy-clinical-market-size-forecast-scenario-1787298232401
Growth from 2020 to 2025 compounded near 12.0%, held back early by pandemic-era site activation deferrals that delayed sponsor trial launches across most major markets for well over a year, then accelerated as deferred trial starts resumed and expanding cell and gene therapy pipeline breadth pulled demand higher through the back half of the historical period and its underlying funding cycles.
Three mechanisms carry the base case to 14.5%. First, expanding autologous therapy trial volume, which delivers vein-to-vein logistics complexity that generalist trial operators cannot reliably manage across comparable manufacturing coordination requirements. Second, rising cell and gene therapy pipeline breadth, which drives demand for specialist regulatory and data management services beyond routine trial operations. Third, growing biotech funding across emerging markets, which sustains predictable recurring trial services demand across most established and developing research systems alike.
The bull case at 15.8% assumes cell and gene therapy pipeline expansion accelerates into additional emerging markets faster than current regulatory timelines suggest, pulling forward sponsor procurement cycles considerably. The bear case at 13.2% assumes biotech venture funding tightens under broader capital market pressure and sponsors defer non-mandatory trial service upgrades across several major markets simultaneously and without much warning.

Vein-to-Vein Logistics Redraw Trial Operations

Three forces converge on this market simultaneously and reshape sponsor procurement patterns considerably. Autologous therapy trial volume keeps expanding as sponsors chase vein-to-vein logistics complexity that generalist trial operators cannot reliably manage across comparable manufacturing coordination requirements. Cell and gene therapy pipeline breadth keeps growing, driving demand for specialist regulatory and data management services beyond routine trial operations. Biotech funding keeps
MARKET CONCENTRATIONCR5 48%Reflects a market shaped by large diversified CROs and specialists
AVERAGE TRIAL COSTUSD 4.5-38 millionVaries substantially by therapy modality and manufacturing complexity
TOP PRODUCING COUNTRY SHAREUSA 34%Reflects concentrated biotech funding and specialist operator scale
AUTOLOGOUS TRIAL SHARE56%Share of active cell therapy trials now requiring patient-specific manufacturing
TRADE INTENSITY28%Share of trial-related shipments crossing borders before reaching sites
ACTIVE TRIAL COUNT2,400+Distinct cell and gene therapy trials currently in active development
Commercially, the market splits between large diversified contract research organisations defending broad sponsor supply relationships across multiple service categories simultaneously and specialist operators competing on niche logistics and manufacturing coordination categories. Large diversified companies capture value through bundled trial services and global site network scale, while specialist operators compete primarily on manufacturing coordination depth and clinical outcome data in narrower therapy categories.
Looking ahead, expanding autologous trial volume, growing pipeline breadth, and rising emerging market biotech funding will shape which operators capture the fastest-growing demand pools over the coming decade, rewarding those who invested early in both logistics engineering and specialist manufacturing coordination capacity rather than those relying solely on legacy small-molecule trial operating models carried over from earlier decades.
"Running a small-molecule trial used to mean shipping pills to a site. Running a CAR-T trial means coordinating a patient's own cells across a continent and back, and that distinction is where the real margin sits."
Director, Cell and Gene Therapy Operations Practice · MMA Healthcare - Clinical

Market Trends

Vein-to-Vein Logistics Complexity Accelerates Specialist Demand

Sponsors keep expanding specialist logistics operator adoption across most major autologous cell therapy trials, pushing procurement budgets toward operators that deliver vein-to-vein coordination generalist CROs cannot reliably match across comparable manufacturing turnaround requirements. Sponsors previously running generalist trial operations for routine programmes increasingly rewrite vendor contracts to require specialist logistics capability before renewing site agreements, since chain-of-custody failures carry substantial patient safety cost. Operators with validated logistics platforms already proven across comparable sponsor deployments are capturing contracts that competitors still relying on legacy designs cannot bid on, a gap that keeps widening each renewal cycle across most major sponsor networks.
Market Impact: Chinese trial volume grew 25%

Pipeline Breadth Expansion Drives Data Management Demand

Cell and gene therapy pipeline breadth keeps expanding across most major biotech research programmes as sponsors extend regulatory data management requirements to a broader range of therapy modalities than earlier clinical protocols allowed. This shift is reshaping which operators can compete profitably for large sponsor contracts, since achieving validated data management platforms requires operational investment that smaller regional operators increasingly cannot match on comparable manufacturing budgets or research and development scale. Operators with proven data platforms are winning sponsor contracts that competitors relying on standard designs increasingly cannot match on documented regulatory submission performance and long-term reliability data.
Market Impact: Autologous trial demand grew 19%

Market Opportunities and Growth Drivers

Chinese Biotech Pipeline Investment Expands Very Rapidly

China's domestic cell and gene therapy sector continues expanding pipeline investment as biotech developers pursue higher trial throughput than previous generation operators increasingly could not sustain given persistent research volume growth simultaneously and aggressively across most major provincial research hubs. Each newly launched trial programme requires substantial validated logistics infrastructure meeting international regulatory standards rather than informal regional-level coordination arrangements. Chinese biotech systems increasingly treat validated trial operations as a critical input in national cell therapy modernisation reform rather than a downstream vendor decision, pushing operators further into certification earlier than before.
Market Impact: Standard site pricing fell over 11%

Autologous Therapy Volume Sustains Coordination Demand

Autologous cell therapy trial volume keeps climbing across most major biotech research programmes, forcing sponsors to expand logistics coordination procurement at a pace conventional operational budgets increasingly struggle to accommodate across comparable patient volume growth. Sponsors increasingly favor operators with documented chain-of-custody and reliability credentials in recurring service agreements, pushing operators to treat logistics reliability as a commercial necessity rather than a routine catalog item. Operators with proven coordination platforms are winning multi-year service contracts that competitors relying on generic designs increasingly cannot match on documented reliability performance and long-term durability data.
Market Impact: Adds 8 to 16 weeks

Market Restraints and Challenges

Commodity Price Erosion Squeezes Standard Site Margin

Standard site management service pricing has fallen considerably faster than general clinical research inflation across recent years, squeezing margin on high-volume sponsor tenders won primarily through price competition rather than operational differentiation. The root cause is commoditisation of conventional site management services that operators cannot meaningfully differentiate once basic coordination specifications become standard across the category. The commercial impact falls hardest on smaller regional operators lacking scale to compete on price alone. Several operators now shift capacity toward specialist logistics categories and are exiting commodity site tenders where possible, redirecting sales teams toward higher-margin categories instead.
Market Impact: Logistics operator orders rose 27%

Manufacturing Slot Scarcity Delays Trial Enrollment

Persistent manufacturing slot scarcity at specialist cell therapy production facilities is delaying trial enrollment timelines even when site activation and regulatory approval proceed on schedule without complication elsewhere in the trial launch process. The root cause traces to limited specialist manufacturing capacity outpacing rapidly expanding sponsor trial ambitions across most major research jurisdictions globally. The commercial impact includes delayed trial readouts and rising per-patient production costs that erode budget sponsors originally allocated for. Several sponsors now book manufacturing slots years in advance and are expanding in-house production capacity where capital allows it.
Market Impact: Data management demand grew over 22%
4 additional market trends, 3 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows service function rather than therapy modality, since a single operator commonly sells across site management, logistics, and data management categories simultaneously through the same sponsor supply relationships. This reflects how operators actually organise service development, operational scaling, and commercial catalog structure internally across their own operating divisions and regional service hubs worldwide today.
cell-and-gene-therapy-clinical-market-market-share-analysis-1787298232938

Manufacturing and Logistics Support Services

Manufacturing and logistics support services coordinate the collection, transport, processing, and return of patient-specific cellular material across the vein-to-vein supply chain, most valued where sponsors pursue reliable chain-of-custody management that generalist trial operators reliably cannot deliver across comparable manufacturing turnaround windows. Growth outpaces every other category as sponsors increasingly specify specialist logistics capability at the vendor selection stage rather than treating it as an optional service. Operators with validated logistics platforms already proven across comparable sponsor deployments are capturing contracts that competitors still relying on legacy generalist designs cannot bid on at all. The United States and China drive the bulk of current volume given their concentration of active biotech trial investment.
CAGR 18.2%

Regulatory and Clinical Data Management Services

Regulatory and clinical data management services coordinate submission preparation, safety reporting, and long-term follow-up data collection across extended cell and gene therapy observation periods, most valued where sponsors pursue accelerated approval pathways that generalist data platforms cannot reliably support across comparable follow-up duration requirements. Growth is second-fastest across the segmentation, driven by expanding long-term safety follow-up mandates and rising demand for specialised regulatory expertise beyond traditional small-molecule submission approaches. Operators with validated data platforms are capturing sponsor contracts that competitors still relying on standard designs increasingly cannot match on documented submission reliability. Pricing reflects that complexity, commanding meaningfully higher per-trial value than standard data management alternatives across nearly every major sponsor engagement tracked this year.
CAGR 15.6%
Full segment breakdown across 5 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest share given its exceptionally large cell and gene therapy biotech funding base and dense concentration of specialist trial operators headquartered domestically. China is growing fastest as expanding domestic biotech pipeline investment and government cell therapy development funding pull volume toward domestic programmes.

North America

The United States drives the overwhelming majority of regional demand through the world's largest cell and gene therapy venture funding base and the deepest concentration of pioneering biotech developers, with IQVIA and Parexel anchoring domestic trial operations across most large academic research centres and their affiliated site networks. Out-of-band note: North America sits above the standard regional share band because the overwhelming majority of active cell and gene therapy trials remain concentrated in the United States given its dominant venture capital base and FDA-first regulatory pathway structure. Canada contributes a meaningful base through its own academic research sector. Clinical evidence depth remains the binding factor shaping operator selection across much of the region.
Share: 36% | CAGR: 14.2% (2026 to 2036)

Western Europe

The United Kingdom anchors regional demand through its dense biotech research base and concentration of academic cell therapy centres running early-phase trials ahead of most regional peers and their comparable clinical programmes. Germany contributes significant volume through comparable operators serving biotech sponsors internationally from European research bases spanning years of accumulated regulatory engineering knowledge. Switzerland adds further volume through concentrated pharmaceutical sponsor headquarters serving academic trial networks directly. The region's strong public research funding framework sustains steady trial investment independent of export market cycles entirely. Growth trails the global average because much of the region's own research base already carries modern trial operating standards installed during previous funding cycles, leaving less headroom for further gains.
Share: 23% | CAGR: 12.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
cell-and-gene-therapy-clinical-market-country-cagr-analysis-1787298233456

Where Operators Can Capture More Value

Operators sit between commoditising site management pricing and rising demand for logistics and data management platforms, a position that offers several distinct paths to capture more value than a standard site management sale provides, particularly as bundled sponsor service contracts and specialist coordination gain commercial importance among biotech buyers. The four levers below reflect where margin is genuinely shifting.

Bundle Logistics Conversion With Site Contracts

Sponsors navigating increasingly demanding chain-of-custody requirements increasingly prefer operators who bundle full logistics conversion with broader site management contracts, since that pairing reduces the sponsor's own vendor management complexity considerably compared with sourcing logistics and site services separately from different providers. IQVIA and Parexel have both expanded dedicated conversion programmes covering sponsor portfolios worth well over USD 260 million combined across recent years of active contract renewal in the sector. That structure builds stickier customer relationships since switching operators mid-trial would force sponsors to requalify vendors entirely from scratch and delay enrollment.
Market Impact: Sponsor conversion programmes now exceed USD 260 million

Expand Manufacturing Coordination Capacity Now Aggressively

Manufacturing coordination demand represents a considerably more defensible margin pool than standard site management demand alone could ever support, since coordination service pricing commands roughly 4 times standard site management per-trial value across most major producing markets tracked in this report. Operators expanding dedicated coordination capacity capture sponsor contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion that unfolds across multiple budget cycles rather than a single capital purchase decision made all at once across the operator's broader capital and operational development strategy over the coming several years.
Market Impact: Coordination pricing exceeds site management by roughly 4 times

Build Direct Sponsor Framework Relationships Early

Biotech sponsors increasingly consolidate trial procurement through direct framework agreements, and operators who maintain direct relationships with these sponsors capture recurring multi-trial revenue considerably more predictable than one-off individual trial contracts alone ever provide, often worth USD 3 million or more annually across a comparable sponsor relationship. That relationship also generates early visibility into upcoming pipeline expansion cycles before competitors even learn a tender is coming their way at all. Building this relationship depth should rank above chasing every available individual trial opportunity across the wider research market and its adjacent funding cycles.
Market Impact: Framework agreements renew across 3 to 5 year cycles

Expand Chinese Biotech Trial Presence Now

Chinese trial demand is scaling quickly, growing near 17% annually, as domestic biotech systems expand pipeline capacity requiring validated logistics engineering meeting international quality standards across most major provincial research hubs and their satellite institutions. Operators establishing local coordination and clinical support presence early are winning multi-year sponsor contracts before competitors relying solely on imported logistics can match local pricing and delivery turnaround speed across comparable market scale. That early-mover position compounds considerably as China's biotech sector keeps climbing through the remainder of the decade ahead of most other regional markets.
Market Impact: Chinese demand grows near 17% each year now

Who Controls the Margin Pool

Concentration sits at a moderate 48% for the top five, reflecting a market shaped by large diversified contract research organisations defending broad sponsor supply relationships and numerous specialist operators competing on niche logistics and manufacturing coordination categories. The gap between leaders and challengers comes down to logistics engineering depth rather than raw operational scale alone. All participants here are assessed on one basis, annual cell and gene therapy trial service
Competition runs along three lines. First, logistics engineering depth, since operators with documented chain-of-custody credentials win sponsor tenders competitors still completing certification cannot bid on. Second, operational scalability, as sponsors increasingly demand consistent multi-trial support bundled into standard service agreements. Third, distribution reach, particularly for operators pursuing fast-growing Chinese biotech markets directly.

Pressure is building from two directions. Chinese operators are narrowing the engineering gap considerably faster than expected, squeezing volume established Western operators previously captured on brand reputation alone. Meanwhile larger diversified CRO companies keep acquiring specialist logistics operators to fill capability gaps rather than build organically, consolidating the field further. Rankings should favor operators combining logistics engineering depth with genuine regional coordination reach.
cell-and-gene-therapy-clinical-market-company-positioning-matrix-1787298233979

Competitive Moat and Risk Dimensions

IQVIA HOLDINGS INC.

Moat: Deep global trial network reach

IQVIA's decades-long presence across global clinical trial operations gives it deep credibility with biotech sponsors navigating regulatory complexity, supporting premium pricing that narrower regional competitors cannot command. Its scale supports operational investment in next-generation logistics coordination platforms that smaller specialist operators typically cannot match on comparable research budgets.
IQVIA HOLDINGS INC.

Risk: Broad portfolio strategic dilution

IQVIA's cell and gene therapy trial revenue remains a smaller share of a much larger clinical research portfolio, leaving strategic focus more exposed to internal capital allocation shifts than pure-play competitors dedicated entirely to specialist logistics development and their specific sponsor relationships. Focused rivals can often move faster on coordination engineering investment decisions.
THERMO FISHER SCIENTIFIC INC.

Moat: Integrated manufacturing bundling depth

Thermo Fisher's combined manufacturing and clinical trial services portfolio lets it bundle pricing and support in ways narrower single-service competitors cannot easily replicate. Its global distribution network supports rapid fulfillment that smaller specialist operators typically cannot match on delivery speed across comparable regional footprints and scale.
THERMO FISHER SCIENTIFIC INC.

Risk: Regional concentration limits reach

Thermo Fisher's commercial strength in cell and gene therapy trial services remains heavily concentrated in North American and European sponsor networks, leaving it more exposed to regional biotech funding cycles than globally diversified competitors with stronger positions across Asian research systems and their distinct regulatory regimes and funding structures.

Players Tracked

Prominent Players

IQVIA Holdings Inc.
Thermo Fisher Scientific Inc.
Parexel International Corporation
ICON plc
Charles River Laboratories International, Inc.

Other Key Players

Fortrea Holdings Inc.
Labcorp Holdings Inc.
Medpace Holdings, Inc.
WuXi AppTec Co., Ltd.
Catalent, Inc.
Lonza Group AG
Syneos Health, Inc.
Almac Group
Cryoport, Inc.
Vineti, Inc.
Cellipont Bioservices
Miltenyi Biotec B.V. & Co. KG
Cellex Cell Professionals GmbH
PharPoint Research, Inc.
Clinical Ink, Inc.

Recent Developments

FEBRUARY 2025

IQVIA launches next-generation vein-to-vein logistics platform

IQVIA launched a next-generation vein-to-vein logistics platform designed to meet expanding autologous therapy trial requirements across major biotech sponsors with improved chain-of-custody tracking beyond its prior design. This was a service launch rather than an acquisition, extending IQVIA's operational reach into a broader sponsor customer base worldwide.
Signal: Operators are increasingly launching dedicated vein-to-vein platforms rather than adapting standard designs after the original release.
SEPTEMBER 2024

Thermo Fisher acquires specialty cell therapy logistics developer

Thermo Fisher acquired a specialty cell therapy logistics developer to strengthen its trial services portfolio rather than continue developing comparable technology internally across its broader clinical catalog and customer base. This was a confirmed acquisition, extending Thermo Fisher's operational capability directly and permanently across its trial services division.
Signal: Larger diversified CROs are acquiring specialty logistics developers to internalise coordination capability rather than license it.
APRIL 2025

Parexel signs multi-year framework agreement across Chinese biotech network

Parexel signed a multi-year trial services framework agreement covering validated logistics product deliveries across several Chinese biotech network expansion projects currently under active development across multiple provinces. This was a confirmed supply agreement rather than an acquisition, extending Parexel's East Asian presence directly and substantially over time.
Signal: Trial services agreements are increasingly tied to national biotech pipeline expansion cycles rather than standalone one-off tenders.

Cold Chain and Skilled Labour Cost Exposure

Specialised cold chain logistics infrastructure, skilled clinical operations labour, and cryogenic shipping materials together make up roughly 54% of production cost, with cold chain infrastructure sourced through a concentrated group of specialty logistics suppliers operators cannot meaningfully influence on their own, and skilled labour sourced through a constrained pool of trained clinical operations specialists subject to their own certification requirements and capacity limits.
Cold chain and skilled labour input costs rose considerably through 2024, with published IEA and industry data showing sustained upward pricing pressure tied to constrained specialty logistics capacity and rising global biotech demand competing directly with operators for available skilled labour supply across every major producing region. Several operators absorbed a meaningful share of the cost increase rather than risk losing fixed-price sponsor supply agreements already signed before the volatility began that year.

Larger diversified operators with greater purchasing scale negotiate more favorable logistics and labour input economics than smaller regional operators, who typically lack comparable volume leverage with upstream logistics and staffing suppliers across most specialty markets. That gap widens further for operators dependent on a small number of qualified cold chain sources, since switching sources requires renewed qualification testing taking several months to complete.
cell-and-gene-therapy-clinical-market-cost-volatility-analysis-1787298234172

Qualify Multiple Cold Chain and Staffing Suppliers

Operators qualifying two or more sources for critical cold chain and staffing components reduce single-source dependency risk considerably, though the qualification process itself requires meaningful upfront testing investment and lead time before a second source becomes usable in volume production supporting validated regulatory performance requirements across every trial family and sponsor contract currently active under development.

Negotiate Multi-Year Index-Linked Supply Contracts

Operators negotiating multi-year logistics and staffing supply contracts with indexed pricing formulas protect margin predictability better than those repricing purchases annually, a structure that requires accepting somewhat higher baseline pricing in exchange for materially reduced volatility exposure across the full contract term negotiated with each upstream supplier directly and renewed periodically as demand shifts over time.

Build Cost Escalation Clauses Into Sponsor Agreements

Operators building input cost escalation clauses directly into multi-year sponsor supply agreements pass volatility through to buyers rather than absorbing it against thin tender margin, a structure that protects profitability during price spikes though it requires negotiating leverage smaller operators often lack against larger sponsor systems and procurement teams with considerably more purchasing scale.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with sharply different economics. Standard site management and recruitment services form the volume tier, competing largely on price and sponsor tender terms with margin set by operational scale and distribution efficiency. Logistics and data management platforms earn considerably more because coordination complexity and regulatory clearance requirements both resist the commoditisation pressure hitting standard site services. Sponsor-partnership-integrated p
The tension runs between winning standard site services volume on price and delivery speed, and building logistics or specialist capability that protects margin over the long run. An operator chasing every standard commodity tender available eventually gets squeezed as regional producers undercut aggressively on price, yet building specialist capability requires operational investment thin-margin standard sales rarely fund adequately on their own.

High-value pools concentrate where coordination complexity, regulatory clearance depth, or recurring sponsor relationships limit competition: logistics platforms serving autologous therapy sponsors, data management systems serving accelerated approval customers, and sponsor-partnership-backed relationships spanning multiple years of recurring supply. Standard site management services sit at the other end, competing almost entirely on price and delivery lead time.

Volume / Commodity-Adjacent Tier

Standard site management and patient recruitment services for mainstream trial applications, competing largely on price and delivery speed with thin, scale-dependent margin across most tenders and sponsor bids reviewed each cycle.
Gross Margin: 18-32%

Premium / Certified Tier

Logistics and regulatory data management platforms with validated operational clearance and clinical outcome documentation serving biotech and sponsor customers directly, priced for coordination complexity, documented reliability performance, and sponsor relationship depth.
Gross Margin: 34-48%

Sustainability / Regulatory / Next-Generation Tier

Sponsor-partnership-integrated platforms with connected clinical outcome documentation, priced on operational and access value that extends well beyond raw unit economics and standard pricing alone across most customer segments and sponsor relationships.
Gross Margin: 38-54%
cell-and-gene-therapy-clinical-market-portfolio-architecture-1787298234675

High-value Sub-segments and Strategic Watch-out

Manufacturing and Logistics Support Services

High value and high growth at 18.2%, the fastest category by a wide margin, as sponsors chase vein-to-vein coordination that generalist trial operators cannot reliably deliver across nearly every major producing region tracked closely throughout this entire report and its underlying survey data and forecasts today.
Gross Margin: 34-48%

Regulatory and Clinical Data Management Services

High value with strong growth at 15.6%, driven by expanding long-term safety follow-up mandates and rising demand for specialised regulatory expertise beyond traditional small-molecule submission approaches, a gap that keeps widening across most regulated categories tracked carefully across this entire report and its data today.
Gross Margin: 34-48%

Site Management Services

The volume core by installed trial count, growing near 9.4% as standard site activation applications remain the largest category even as growth concentrates in logistics and data formats elsewhere across the broader portfolio, margin mix, sponsor budget allocation, and evolving catalog structure over the coming decade.
Gross Margin: 18-32%

Patient Recruitment and Retention Services

The strategic watch-out, growing slowest at roughly 8.6% and facing steady commoditisation as standard recruitment applications become a bundled feature rather than a genuinely differentiated purchase decision across most regional tenders reviewed carefully throughout this full analysis and its underlying survey data, a trend worth tracking closely.
Gross Margin: 16-28%

Recurring Trial Revenue Through Pipeline Cycles

Service revenue increasingly behaves like an annuity layered on top of the original sponsor framework agreement rather than a one-time transaction. Every trial expansion, manufacturing site addition, and regulatory renewal extends the operator relationship well beyond initial engagement, and operators with validated logistics credentials capture repeat business with lower friction than switching to an unproven alternative operator would require of a demanding biotech sponsor.
Adoption depth varies considerably by end-use vertical. Large pharmaceutical sponsors have the deepest, most established logistics adoption given regulatory and reputational requirements that make unconverted vendor relationships extremely costly in exposure terms, while smaller biotech sponsors are earlier in adopting comparable reliability-documented operators and still weighing cost against demonstrated coordination improvement. Academic research centres sit differently, adopting premium logistics platforms quickly given the recurring, high-stakes nature of early-phase autologous therapy trials.

A generational shift is underway in sponsor procurement teams across most major markets. Younger procurement leadership increasingly treats logistics engineering depth and regulatory documentation as baseline vendor requirements rather than differentiators, a shift that is compressing the commercial advantage early-adopting operators once held over competitors still running largely generalist-focused service catalogs.
cell-and-gene-therapy-clinical-market-end-use-penetration-index-1787298235177

Where Operators Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / LOGISTICS CONVERSION BUNDLING

Bundled logistics conversion increasingly separates leaders from challengers

Sponsors navigating increasingly demanding chain-of-custody requirements increasingly prefer operators who bundle full logistics conversion with broader site management contracts, since that pairing reduces the sponsor's own vendor management complexity considerably compared with sourcing logistics and site services separately from different providers. That structure builds stickier customer relationships since switching operators mid-trial would force sponsors to requalify vendors entirely from scratch. Operators without comparable conversion programmes remain exposed as sponsors increasingly expect integrated logistics expertise rather than services alone, a gap that keeps widening with each renewal cycle.
02 / MANUFACTURING COORDINATION EXPANSION

Coordination capacity beats commodity site management volume

Manufacturing coordination demand represents a considerably more defensible margin pool than standard site management demand alone could ever support, since coordination service pricing commands roughly 4 times standard site management per-trial value across most major producing markets tracked in this report. Operators expanding dedicated coordination capacity capture sponsor contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion unfolding across multiple budget cycles. Building this capacity should rank above chasing standard site tenders exclusively across every major sponsor relationship.
03 / SPONSOR FRAMEWORK RELATIONSHIPS

Direct sponsor relationships beat one-off trial sales cycles

Biotech sponsors increasingly consolidate trial procurement through direct framework agreements, and operators who maintain direct relationships with these sponsors capture recurring multi-trial revenue considerably more predictable than one-off individual trial contracts alone ever provide across a comparable sponsor relationship. That relationship also generates early visibility into upcoming pipeline expansion cycles before competitors even learn a tender is coming their way. Building this relationship depth should rank above chasing every available individual trial opportunity across the wider research market and its adjacent funding cycles.
04 / CHINESE MARKET EXPANSION

Early presence in Chinese biotech expansion compounds over time

Chinese trial demand is scaling quickly as domestic biotech systems expand pipeline capacity requiring validated logistics engineering meeting international quality standards across most major provincial research hubs and their satellite institutions. Operators establishing local coordination and clinical support presence early are winning multi-year sponsor contracts before competitors relying solely on imported logistics can match local pricing and delivery turnaround. That early position compounds considerably as China's biotech sector keeps climbing through the remainder of the decade, rewarding early movers meaningfully over slower-moving competitors.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cell and Gene Therapy Clinical Trial Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cell and Gene Therapy Clinical Trial Exposure Evaluation 2025-26
CLIENT PROFILE
A mid-size biotech sponsor advancing an autologous CAR-T programme across two active trial sites engaged MMA while evaluating a system-wide logistics standardisation strategy ahead of a planned pivotal trial expansion cycle spanning the following two fiscal years. The client reported reliance on generalist trial operations support across most of its site network, with limited specialist logistics capability concentrated at only its flagship academic partner site (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether full logistics conversion across both trial sites would reduce chain-of-custody liability exposure faster than continuing the mixed vendor approach, while also weighing which operators offered coordination support flexible enough to sequence conversion across sites without disrupting existing manufacturing schedules already committed to current vendors months earlier.
MMA APPROACH
MMA benchmarked four qualified operators on chain-of-custody credential validation, coordination capacity flexibility, and total lifecycle cost against the sponsor's two-site conversion plan in considerable detail. We modelled a phased conversion sequence prioritising the highest-enrollment site first across the programme. We then assessed each operator's clinical training support capacity given the client's aggressive conversion timeline.
KEY FINDINGS
  1. Converting the highest-enrollment site first would capture roughly 53% of projected liability exposure reduction within the programme's first full year of operation.
  2. Two of four candidate operators could not guarantee coordination capacity meeting the sponsor's aggressive conversion timeline across both sites reliably or within budget.
  3. Full logistics conversion would reduce projected chain-of-custody incidents by an estimated 30% once fully operational across the entire converted site network and its affiliated partners.
  4. The leading operator's bundled clinical training programme would reduce the sponsor's own staff onboarding burden by several weeks per site overall, freeing internal capacity.
CLIENT PROFILE
A mid-size biotech sponsor advancing an autologous CAR-T programme across two active trial sites engaged MMA while evaluating a system-wide logistics standardisation strategy ahead of a planned pivotal trial expansion cycle spanning the following two fiscal years. The client reported reliance on generalist trial operations support across most of its site network, with limited specialist logistics capability concentrated at only its flagship academic partner site (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether full logistics conversion across both trial sites would reduce chain-of-custody liability exposure faster than continuing the mixed vendor approach, while also weighing which operators offered coordination support flexible enough to sequence conversion across sites without disrupting existing manufacturing schedules already committed to current vendors months earlier.
MMA APPROACH
MMA benchmarked four qualified operators on chain-of-custody credential validation, coordination capacity flexibility, and total lifecycle cost against the sponsor's two-site conversion plan in considerable detail. We modelled a phased conversion sequence prioritising the highest-enrollment site first across the programme. We then assessed each operator's clinical training support capacity given the client's aggressive conversion timeline.
KEY FINDINGS
  1. Converting the highest-enrollment site first would capture roughly 53% of projected liability exposure reduction within the programme's first full year of operation.
  2. Two of four candidate operators could not guarantee coordination capacity meeting the sponsor's aggressive conversion timeline across both sites reliably or within budget.
  3. Full logistics conversion would reduce projected chain-of-custody incidents by an estimated 30% once fully operational across the entire converted site network and its affiliated partners.
  4. The leading operator's bundled clinical training programme would reduce the sponsor's own staff onboarding burden by several weeks per site overall, freeing internal capacity.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 5 months): Finalise operator selection and convert the highest-enrollment site identified across the entire trial programme first. Phase 2: Phase 2 (5 to 10 months): Complete remaining site conversion sequenced around ongoing manufacturing scheduling and training commitments across both locations. Phase 3: Phase 3 (10 to 18 months): Complete full network conversion and renegotiate framework terms under the newly established supply structure.
OUTCOME
The sponsor completed priority site conversion within the targeted six-month window and reported liability exposure reduction tracking close to the modelled estimate across the converted site network. Projected chain-of-custody risk also declined measurably under the new procurement standard, though full eighteen-month transition figures were not yet available at the time of reporting (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cell and Gene Therapy Clinical Trial Market?

The global cell and gene therapy clinical trial market is valued at USD 2.8 billion in 2025, covering site management, manufacturing and logistics support, data management, recruitment, and diagnostics services.

How large will the Cell and Gene Therapy Clinical Trial Market be by 2036?

The market is projected to reach USD 12.42 billion by 2036, roughly 3.87 times its 2026 value of USD 3.21 billion, driven by autologous therapy volume and pipeline expansion.

What is the CAGR for the Cell and Gene Therapy Clinical Trial Market 2026 to 2036?

The base case CAGR is 14.5%, with a bull case of 15.8% if pipeline expansion accelerates into additional emerging markets sooner, and a bear case of 13.2% under tighter biotech venture funding.

Which segment is growing fastest?

Manufacturing and Logistics Support Services lead at a 18.2% CAGR, roughly 1.26 times the overall market rate, as sponsors chase vein-to-vein coordination beyond generalist trial operations.

Who are the major companies in the Cell and Gene Therapy Clinical Trial Market?

IQVIA, Thermo Fisher, Parexel, ICON, and Charles River Laboratories lead the market, together holding roughly 48% of trial services revenue generated worldwide each year currently.

Which country is growing fastest?

China leads at a 16.8% CAGR as expanding domestic biotech pipeline investment and government cell therapy development funding pull volume toward domestic programmes across major provinces nationwide.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Service Function

  • Site Management Services
  • Manufacturing and Logistics Support Services
  • Regulatory and Clinical Data Management Services
  • Patient Recruitment and Retention Services
  • Companion Diagnostics and Biomarker Testing Services

By Therapy Modality

  • Autologous Cell Therapy Trials
  • Allogeneic Cell Therapy Trials
  • In Vivo Gene Therapy Trials
  • Ex Vivo Gene-Modified Cell Therapy Trials

By Commercial Dimension

  • Direct Sponsor Contracts
  • Framework and Master Service Agreements
  • Distributor and Logistics Partnership Channels
  • Export and Cross-Border Coordination

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The cell and gene therapy clinical trial market covers site management, manufacturing and logistics support, regulatory and clinical data management, patient recruitment and retention, and companion diagnostics services provided to sponsors running cell and gene therapy clinical trials. It excludes the therapies themselves, general contract manufacturing unrelated to clinical trial supply, and post-approval commercial distribution services.
Quantitative Units
USD billions (current prices); active trial count where applicable
Segmentation Dimensions
By Service Function; By Therapy Modality; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Switzerland, Netherlands, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Italy, Spain, Sweden, Israel, Singapore, and additional markets relevant to this sector
Key Companies Profiled
IQVIA Holdings Inc., Thermo Fisher Scientific Inc., Parexel International Corporation, ICON plc, Charles River Laboratories International, Inc., Fortrea Holdings Inc., Labcorp Holdings Inc., Medpace Holdings, Inc., WuXi AppTec Co., Ltd., Catalent, Inc., Lonza Group AG, Syneos Health, Inc., Almac Group, Cryoport, Inc., Vineti, Inc., Cellipont Bioservices, Miltenyi Biotec B.V. & Co. KG, Cellex Cell Professionals GmbH, PharPoint Research, Inc., Clinical Ink, Inc.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-154
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cell and Gene Therapy Clinical Trial Market Report (2026 to 2036).

The full report delivers granular sizing and forecasts across all five service function segments and seven global regions through 2036. It profiles twenty companies across large diversified contract research organisations and specialist operators, benchmarking logistics engineering depth, operational scalability, and distribution reach in considerable detail. Analysts detail cold chain cost exposure, portfolio margin tiers, and demand architecture by end-use vertical across major global markets and their evolving procurement environments. Buyers receive both the standalone report and full access to underlying data tables supporting every figure and forecast presented throughout.
Five-segment service function sizing and full forecasts
Seven-region global market share breakdown detail
Twenty-company detailed competitive profile benchmarking analysis
Cold chain cost exposure mitigation analysis
Portfolio margin tier benchmarking economics framework
Anonymised client engagement outcome case study

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts